Vps33b pathogenic mutations preferentially affect VIPAS39/SPE-39-positive endosomes

Area of Science:

• Cell Biology
• Genetics
• Molecular Biology

Background:

• Mutations in Vps33 isoforms lead to various phenotypes, including pigment dilution and human diseases like arthrogryposis, renal dysfunction, and cholestasis syndrome (ARC).
• VIPAS39 (VPS33B interacting protein, SPE-39 homolog) mutations also cause ARC syndrome (ARC2) and interact with the HOPS complex, crucial for endosome-lysosome traffic.

Purpose of the Study:

• To investigate the molecular and cellular mechanisms underlying VIPAS39 and Vps33b interactions in the context of ARC syndrome.
• To elucidate how disease-causing mutations in VIPAS39/SPE-39 and Vps33b affect their interaction and subcellular localization.

Main Methods:

• Yeast two-hybrid assays to assess protein-protein interactions.
• Immunoprecipitation to confirm interactions in a cellular context.
• Quantitative fluorescent microscopy to analyze subcellular localization and endosome morphology.

Main Results:

• While most mutations did not prevent VIPAS39/SPE-39 and Vps33b interaction, some altered VIPAS39/SPE-39-positive endosome morphology.
• All tested mutations affected the subcellular localization of Vps33b to VIPAS39/SPE-39-positive endosomes.
• These findings indicate a role for VIPAS39 and Vps33b in endosomal maturation and fusion processes.

Conclusions:

• The study suggests that impaired VIPAS39/SPE-39 and Vps33b interactions and altered localization contribute to ARC syndrome pathogenesis.
• VIPAS39 and Vps33b are critical for normal endosomal maturation and fusion, processes essential for metazoan cell function.